ADVENT THERAPEUTICS
Vitamin A reinvented for Neonatal & Pediatric Care
​
Committed to developing life-changing medicines for the most-fragile preterm infants and patients with other unmet medical needs
About Us
Advent Therapeutics is a late-stage neonatology and rare disease biopharmaceutical company pioneering life-changing medicines for extremely preterm infants. We are focused on addressing a very serious respiratory disease called bronchopulmonary dysplasia (BPD) which is the most common serious complication of prematurity and causes lung damage that leads to prolonged NICU stays, a range of comorbidities that can include long-term lung damage, and even death
Advent is committed to preventing and treating BPD by advancing its proprietary formulations of retinol palmitate (vitamin A) as novel metabolic and reparative therapies specifically optimized for preterm infants
Advent’s BPD programs have been supported extensively by the National Institutes of Health (NIH) and the Commonwealth of Pennsylvania. The Company maintains laboratory and office space at the Pennsylvania Biotechnology Center (PABC) in Bucks County
Pipeline
Advent’s Metabolic & Reparative Technology
Advent has designed its proprietary water miscible vitamin A palmitate drug products for optimal administration to fragile preterm neonates. The drugs do not contain chlorobutanol (an alcohol) or other preservatives that may be of concern with respect to sensitivity or potential toxicity
Advent’s formulation of vitamin A comes in two methods of application: intramuscular (IM) and aerosolized products for use in NICUs as orphan drugs to address unmet medical needs such as BPD, retinopathy of prematurity (ROP), and acute lung injury (ALI)
Vitamin A plays a key role in preventing neonatal BPD
Neonatal BPD | serious problem with no approved therapy
Bronchopulmonary Dysplasia (BPD) is a chronic respiratory disease requiring oxygen supplementation and ventilatory support with extensive, costly stays at hospital’s Neonatal Intensive Care Unit (NICU)
​
BPD is the most common serious morbidity of prematurity[1]. The earlier the birth, the lower the infant’s weight , the higher the probability of BPD occurrence. BPD is strongly associated with vitamin A deficiency and is addressable with effective & safe supplementation
​
NIH considers BPD a severe unmet need
1 - Thébaud, B., et al. Bronchopulmonary dysplasia. Nat Rev Dis Primers 5, 78 (2019)
2 - US Department of Health & Human Services, Agency for Healthcare Research and Quality (AHRQ), H-CUPnet, Rockville, MD
3 - Lapcharoensap et al. Hospitalization costs associated with bronchopulmonary dysplasia in the first year of life. J Perinatol 40, 130–137 (2020)
4 - Bhandari A, et al., BPD Following Preterm Birth: A Model for Chronic Lung Disease and a Substrate for ARDS in Childhood. Front Pediatr. 2016 15;4:60.